×
About 8,945 results

ALLMedicine™ Leukemias Center

Research & Reviews  2,312 results

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
https://clinicaltrials.gov/ct2/show/NCT03805932

Jan 27th, 2023 - Background: Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias, or approximately 1200 of the 62,130 new cases of leukemia/year in the US. HCL variant (HCLv), also CD22+, is 10-20% as common as HCL, but mo...

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
https://clinicaltrials.gov/ct2/show/NCT05237986

Jan 27th, 2023 - Background: Chimeric antigen receptor (CAR) T-cell immunotherapy has rapidly emerged as a successful and breakthrough treatment in pediatric and adult hematologic malignancies. However, significant toxicities can complicate the therapeutic success...

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
https://clinicaltrials.gov/ct2/show/NCT04815356

Jan 26th, 2023 - Background Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias. Most cases of HCL respond well to purine analog chemotherapy and harbor BRAF V600E mutation that can be considered for targeted treatment at ...

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
https://clinicaltrials.gov/ct2/show/NCT04324112

Jan 26th, 2023 - Background: Hairy cell leukemia (HCL) is an indolent B-cell leukemia comprising 2% of all leukemias, or approximately 1900 new cases/year in the US. The nucleoside analogs cladribine and pentostatin are highly active as monotherapy with complete r...

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lym...
https://clinicaltrials.gov/ct2/show/NCT05105841

Jan 26th, 2023 - Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries, representing approximately 30% of all adult leukemias. There is a large difference in proportion of malignant lymphoma between the United States (US) and Japan wa...

see more →

Guidelines  2 results

Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0165
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Byrd JC et. al.

Nov 10th, 2017 - Hairy cell leukemia (HCL) is a rare type of indolent B-cell leukemia, characterized by symptoms of fatigue and weakness, organomegaly, pancytopenia, and recurrent opportunistic infections. Classic HCL should be considered a distinct clinical entit...

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0116
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...

see more →

Drugs  417 results see all →

Clinicaltrials.gov  237 results

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
https://clinicaltrials.gov/ct2/show/NCT03805932

Jan 27th, 2023 - Background: Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias, or approximately 1200 of the 62,130 new cases of leukemia/year in the US. HCL variant (HCLv), also CD22+, is 10-20% as common as HCL, but mo...

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
https://clinicaltrials.gov/ct2/show/NCT05237986

Jan 27th, 2023 - Background: Chimeric antigen receptor (CAR) T-cell immunotherapy has rapidly emerged as a successful and breakthrough treatment in pediatric and adult hematologic malignancies. However, significant toxicities can complicate the therapeutic success...

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
https://clinicaltrials.gov/ct2/show/NCT04815356

Jan 26th, 2023 - Background Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias. Most cases of HCL respond well to purine analog chemotherapy and harbor BRAF V600E mutation that can be considered for targeted treatment at ...

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
https://clinicaltrials.gov/ct2/show/NCT04324112

Jan 26th, 2023 - Background: Hairy cell leukemia (HCL) is an indolent B-cell leukemia comprising 2% of all leukemias, or approximately 1900 new cases/year in the US. The nucleoside analogs cladribine and pentostatin are highly active as monotherapy with complete r...

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lym...
https://clinicaltrials.gov/ct2/show/NCT05105841

Jan 26th, 2023 - Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries, representing approximately 30% of all adult leukemias. There is a large difference in proportion of malignant lymphoma between the United States (US) and Japan wa...

see more →

News  605 results

Mastocytosis: Rare, underdiagnosed, potentially fatal
https://www.mdedge.com/hematology-oncology/article/260749/mixed-topics/mastocytosis-rare-underdiagnosed-potentially-fatal
Helen Leask, PhD

Jan 24th, 2023 - Systemic mastocytosis is widely underdiagnosed, and many more hematologic oncologists should be looking for it. This call to action was issued late in 2022 by Stanford (Calif.

First Patient Dosed With Menin Inhibitor BMF-219 in COVALENT-101 Trial in CLL
https://www.onclive.com/view/first-patient-dosed-with-menin-inhibitor-bmf-219-in-covalent-101-trial-in-cll

Nov 21st, 2022 - The first patient in the chronic lymphocytic leukemia (CLL) cohort has been dosed in the phase 1 COVALENT-101 trial (NCT05153330), which is evaluating the first-in-class covalent menin inhibitor BMF-219, in patients with relapsed/refractory acute ...

Treatments for MCL Continue to Progress
https://www.onclive.com/view/treatments-for-mcl-continue-to-progress

Nov 18th, 2022 - As research and treatment options for patients with mantle cell lymphoma (MCL) continue to expand, the development of risk-adapted therapies for the 3 primary subtypes—blastoid, smoldering, and classic broad-spectrum—represents a crucial next step...

CAR Therapy Era Moves Forward With Much Excitement, Lingering Questions
https://www.onclive.com/view/car-therapy-era-moves-forward-with-much-excitement-lingering-questions

Nov 16th, 2022 - CAR T-cell therapies have generated considerable enthusiasm in the oncology community since the first FDA approval in 2017. From a clinical standpoint, these therapies have significantly improved outcomes in disease settings where the outlook for ...

Innovations Are Poised to Lead MPN/MDS Treatment Landscape in a Positive Direction
https://www.onclive.com/view/innovations-are-poised-to-lead-mpn-mds-treatment-landscape-in-a-positive-direction

Nov 9th, 2022 - A full day of programming on hematologic malignancies will kick off the 40th Annual Chemotherapy Foundation Symposium. Included in the lineup highlighting advances in multiple myeloma, leukemias, lymphomas, and other issues across malignancies, a ...

see more →

Patient Education  5 results see all →